CVS Group has described the competition regulator's final remedies as in line with expectations, while reporting higher full-year profits and a solid start to its new financial year.
CVS Group (LSE:CVSG), the FTSE 250 veterinary services provider, has gained greater clarity on its regulatory landscape. Final results published on 24 September came just two days after the Competition and Markets Authority published its final remedies order following its market investigation into the UK veterinary sector. The company said the outcome was in line with its expectations, and it has continued buying back shares, with notices filed most weeks including on 5 October.
Results show steady growth
For the year to 30 June 2026, Revenue rose 5.9% to £712.8m. Like-for-like sales growth improved to 2.1% from 0.2% the previous year. Adjusted EBITDA increased 5.1% to £141.5m, giving a Margin of 19.9%, within the company's target range of 19% to 23%. Adjusted Earnings Per Share rose 6.9% to 85.6p, and the board proposed a final Dividend of 9.0p, up from 8.5p.
Net bank borrowings increased to £199.6m from £131.4m, reflecting acquisitions and buybacks, though Leverage remained moderate at 1.63 times, below the company's two times threshold. Chief executive Richard Fairman described the year as one of solid growth across all three divisions and said the Business was well placed for long-term growth. Mr Fairman has also announced his intention to retire once a successor has been appointed.
Regulatory clarity
The CMA's investigation into the veterinary market had been a significant overhang for the sector, with concerns raised over pricing transparency and competition. According to CVS, the final remedies are largely focused on transparency, including requirements around pricing information for pet owners. The company expects implementation costs of around £5.1m. With the review now concluded, attention is turning to how practices adapt to the new requirements and whether they affect pricing or customer behaviour over time.
Expansion and Capital returns
CVS has been expanding in Australia, where revenue grew to £79.1m from £52.1m and now accounts for about 11% of the group total. Its Australian estate has increased to 57 sites from 43 following the Acquisition of six practices. Since the year-end, the company has agreed further deals, including two in Australia and a two-site UK practice for an initial £15.0m.
Capital returns remain a feature. After completing a £20m buyback in January, CVS launched a further £50m programme in May, which had reached £11.7m by the end of June and is expected to conclude by November.
The company said its new financial year had started solidly, with positive like-for-like growth, and that trading was in line with market expectations. It cited analyst consensus of about £150.4m of adjusted EBITDA and 94.9p of adjusted earnings per share for the current year. The board remains confident of returning to organic like-for-like growth of 4% to 8% over the medium term.
The UK pet care market has historically proved resilient, supported by high levels of pet ownership and rising spending on animal health, although cost-of-living pressures have encouraged some owners to defer non-essential treatment. Staff recruitment and retention, particularly of veterinary surgeons, remains a sector-wide challenge.
For FTSE 250 investors, the main items to watch are the implementation of CMA remedies, progress on chief executive succession, the pace of acquisitions in Australia and whether like-for-like growth accelerates towards the medium-term range.
_11_18_2026_06_43_20_247880.jpg)





Please wait processing your request...